-

Invenra Unveils Rapid Bispecific Antibody Discovery Services – 4 Months from Start to Finish

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific Platform, the streamlined service can identify bispecific antibody lead panel candidates in as little as four months.

With these accelerated services, Invenra continues to build on its reputation for groundbreaking, client-focused discovery models. Recognizing the critical need for faster timelines in preclinical antibody discovery, the service is designed to meet the growing demand for expedited preclinical discovery on time-sensitive projects.

“Our team is committed to accelerating bispecific antibody discovery without compromising quality or precision,” said Roland Green, CEO. “This new approach harnesses our advanced technologies and refined workflows, empowering both established and early-stage biopharmaceutical companies to meet ambitious timelines and bring innovative treatments to patients faster.”

The new rapid discovery service complements Invenra’s established role as a strategic partner in antibody discovery and development. For those seeking a comprehensive partnered approach, Invenra continues to offer tailored support across all discovery stages, including custom antigen design, cell line generation, assay development, and in-depth biological analysis - each customized to meet the unique objectives of its partner.

About Invenra

Invenra Inc. provides innovative pharmaceutical discovery and development services, specializing in antibody discovery and development for a range of therapeutic applications. For more information, please visit invenra.com.

Contacts

Bryan Glaser
Senior Vice President, Business Development
Invenra Inc.
Phone: 608-441-8319
Email: bglaser@invenra.com

Industry:

Invenra Inc.

Release Versions
English

Contacts

Bryan Glaser
Senior Vice President, Business Development
Invenra Inc.
Phone: 608-441-8319
Email: bglaser@invenra.com

More News From Invenra Inc.

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development

MADISON, Wis, & NORTH BETHESDA, Md.--(BUSINESS WIRE)--Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs. Under the collaboration, Invenr...

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

MADISON, Wis.--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a...

Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (...
Back to Newsroom